News Header

News

Contact us generico

Contact Us

Do you want to know more?

Call us: +39.035.328.111

E-mail us: siad@siad.eu

 

Multi-category-gradle Portlet

Asset entries from categories Portlet

Back

Four abstracts prove the efficacy of SonicOne® O.R. in Wound Care

Misonix was present at the 2016 Diabetic Limb Salvage Conference in Washington D.C
04 Apr 2016

The company has announced that four new abstracts proving the efficacy of ultrasound technology in wound debridement were presented at the 2016 Diabetic Limb Salvage Conference.

The first study showed that following the use of SonicOne O.R. to prepare the wound bed graft site, skin grafts achieved a 90% success rate. Dr Peter Blume, Assistant Clinical Professor of Surgery, Anesthesia and Orthopedics at the Yale School of Medicine, stated that: “SonicOne O.R. is quickly establishing itself as a new standard in wound bed preparation”.

A second study brings new evidence to support the efficacy of ultrasound in reducing bacterial contamination of infected wounds. A 105 reduction in bacterial count was measured immediately post-treatment with SonicOne O.R. “Bacterial infection is one of the leading causes for chronic wounds' failure to heal", commented Dr Michael Baruch, Chief of Section of Plastic and Reconstructive Surgery at St. Joseph Hospital and Medical Center in New Jersey. “Data show the SonicOne O.R. reduces the bacterial load allowing for the patient's wound to heal correctly.”

“As the clinical evidence continues to build, the opportunity exists to establish SonicOne O.R. as the gold standard for wound debridement,” stated Scott Ludecker, Senior Vice President of Global Sales & Marketing for Misonix. “The investment in our wound platform technologies are validated by this clinical evidence. We believe that strong clinical evidence such as that presented at the DLS Conference this year, will further enhance our SonicOne O.R. value proposition to our clinician customers as well as to hospital administrators.”

Michael A. McManus Jr., Misonix President and CEO, added: “We are committed to adding to the body of scientific evidence supporting all of our technologies at Misonix.  The new data presented this week at DLS highlights this commitment to the surgical wound and burn surgeons and their patients.  We are encouraged by this new data and look forward to sharing it with the healthcare community."